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Ideal antiarrhythmic therapy may not impact on AD and tDtal death as sus-
pected; in the ESVEM trial, the 1 and 4 year actuarial mortality from OH AD
was 8% and 18%. These values may indicate more precisely those patients
who benefit from prefect antiarrhythmic therapy. With 8% 1 year OH-AD,
92% cou Id be treated unnecessarily.
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Decreasing Risk of Symptomatic Sustained
Ventricular Tachycardia in Myocardial Infarction
Patients
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nonfatal cardiovascular events and three psychological variables reflecting
aspects of quality of life. Nonfatal cardiovascular events included acute my-
ocardial infarction, incapacitating or unstable angina, cerebrovascular and
peripheral vascular events. The psychological variables were aggregate mea-
sures of psychosomatic symptoms and sleep disturbances and an evaluation
of life satisfaction on a visual analogue scale. The mean age of the patients
was 59 ± 7 years and 30% were women. The patients were followed for a
total of 2887 patient years, with a median follow-up time of 3.6 years. To-
tal cardiovascular mortality in the metoprolol versus verapamit group were
5.4% versus 6.2% and 4.7% versus 4.7% respectively. Nonfatal cardiovas-
cular events occurred in 26.4 and 24.1 %, respectively. Psychosomatic symp-
toms and sleep disturbances were significantly improved in both treatment
groups. The magnitude of change was small and not significantly different.
Life satisfaction did not change on either drug. Withdrawals due to side ef-
fects occurred in 11.1 and 14.6%, respectively.
Conclusion: This large scale long term study shows that both drugs were
well tolerated and had the same effect on mortality, cardiovascular end
points and measures of quality of life.
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Electrophysiologic Findings in Patients with
Obstructive Sleep Apnea Associated Ventricular
Asystole
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Our knowledge Df natural history in survivors following myocardial infarction
(Mil is mainly based on data collected before the fibrinolytic era. In a prospec-
tive risk stratification study, 823 MI survivDrs underwent 24-h Holter moni-
toring (HMl 12-16 days after the acute event. Ventricular extrasystoles (VES)
were present in 77% of the pts, ::: 20 VES/h in 10%. ventricular pairs (VP)
in 27%, ventricular salvoes (VS) in 12% and nonsustained ventricular tachy-
cardias (>5 consecutive VES}(nsVT) in 9%. During the 12-months follow-up
(only one patient was lost) there were 66 (8%) deaths, 26 sudden or instanta-
neous (SD)(39%). 23 non-sudden, 6 non-cardiac and 11 of unknown causes.
SO-rates were 3% in thDse with monomorphic YES, 9% with :;:20 VES/h or
Vp, 10% with VS and 13% with nsVT (p = 0.01). Only one pt developed a
symptomatic sustained ventricular tachycardia 2 months after discharge and
only 5 pts had syncopes of unknown origin.
Conclusion: In the fibrinolytic era, arrhythmias are still as prevalent as at
the time before thrombolysis. The sudden death rate is also similar. However,
symptomatic sustained ventricular tachycardia has become an extremely
rare event.
Fourteen patients (47 ± 11 years) with ventricular asystDle of 5.6 ± 2.7
sec (range: 3.1-13.6 sec) due to complete atrioventricular (AV) block (n =
8). sinoatrial (SA) block or sinus node (SN) arrest (n = 5) or both (n = 1)
occurring exclusively during sleep apnea episodes as documented by car-
diorespiratory polysomnography underwent conventional electrophysiologic
study: evaluation of sinus node function included rate corrected SN recovery
time (CSNRT), sinoatrial conduction time (SACT, Narula method). and sinus
rate (SR) response to atropine (0.02 mglkg). CSNRT of <550 ms, SACT of
<125 ms, and SR increase after atropin to >90 bpm were considered to be
normal. Assessment of AV-conduction included AH- and HV-intervals. AV-
Wenckebach periods, and AV nodal effective refractory periods (ERPs) be-
fore and after atropine. None of the 14 pts received digitalis, beta-blockers
or verapamil during polysomnography or EP study. 6 pts (42%) had hyperten-
sive heart disease, 1 pt (8%) had cDronary disease, and 7 pts (50%) showed
no evidence of structural heart disease.
Results: SN function was normal in 12 of 14 pts (86%). Two pts had slightly
prolonged SACTs (160 and 165 ms respectively). CSNRT and SR response to
atropine was normal in all pts. AV nodal function was normal in 8 of 14 pts
(57%) and abnormal in 4 pts (43%): 2 pts had prolonged AH-intervals Df 135
and 143 ms, and 2 pts had AV-Wenckebach points at 520 and 730 ms and
AV nodal ERPs of 500 and 700 ms respectively. AV-nodal function normalized
after administration of atropine in all 4 pts. His-Purkinje system function was
normal in 8 pts (57%), and 6 pts (43%) had slightly prDlonged HV-Intervals
(range: 59-63 ms). Intra- or infra His block was not observed in any pt.
In conclusiDn. normal or only slightly abnormal electrophysiologic findings
in most patients with sleep apnea associated ventricular asystole support the
hypDthesis that ventricular asystole is due to a neurally mediated cardioin-
hibitory reflex. However, it remains unsolved, why sleep apnea associated
prolonged ventricular asystole does occur in some pts and does not occur
in other pts despite severe obstructive sleep apnea.
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Out-of-Hospital versus In-Hospital Death in the
ESVEM Trial
Potential Impact of Serial Drug Testing on the
Clinical Outcome of Survivors of Cardiac Arrest,
as Assessed in the Propafenone Arm of CASH
Trial
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The study design olthe Cardiac Arrest Study Hamburg (CAS H) trial allows ret-
rospective assessment of serial drug testing (SOT) predictive value. Regard-
less of pts assignment to Dne of the 3 drug arms (propafenone (P), metopro-
101 and amiodarone) all pts undergo programmed electrical stimulation (PES)
before and after oral drug administration; the assigned drug is then adminis-
tered regardless of the response to SOT. DisciDsure of data on P and ICD in
survivors of cardiac arrest after premature termination of the former arm al-
lowed retrospective assessment of the predictive value of SOT. In the P arm,
age was 57 ± 13 yrs; 46 (79%) out Df 58 pts had ischemic heart disease. Dur-
ing baseline PES. a sustained ventricular arrhythmia (sVA) could be induced
in 25 (63%) pts assigned to P After oral P(300-900 mg/day). 13 (52%) among
inducible, but 22 (67%) among nDninducible pts at baseline presented a sVA
in response to PES. During a median follDw-up of 11 months, sVA or sudden
death occurred in 2/13 (15%) nonresponders, 2/5140%) respDnders. in 2/7
(29%) pts who became inducible after P and in 3/22 (14%) whD were not in-
ducible during baseline and after P The second PES could not be performed
in 11 (19%) pts due to the occurrence of spontaneous VA arrhythmias after
P administration; sVA during follow-up were dDcumented in 5 (45%) such
pts. The positive and the negative predictive values of SOT with P were 60%
and 15%, respectively.
Conclusion. Data from this study suggest that. in survivors of cardiac ar-
rest. SOT with P carries a poor predictive value to guide drug therapy. This
observatiDn prompts further investigatiDn to assess the utility of SOT as a
strategy in pts at risk of sudden death.
Brian Olshansky, Vernon Hartz. Elizabeth Hahn, Jay Mason, ESVEM Investigators.
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Perfect antiarrhythmic therapy may not impact on total arrhythmic death (AD)
(defined as death associated with ventricular tachycardia, ventricular fibrilla-
tion or asystole) or all cause mortality if AD is not preventable. Death asso-
ciated with an arrhythmia may occur in-hospital (IH) as an inevitable conse-
quence of the disease process, be considered AD and not be preventable.
Out-of-hospital AD, however, may be preventable by perfect antiarrhythmic
therapy. We evaluated IH-AD, OH-AD, non-arrhythmic cardiac death ICARI,
non-cardiac death (NCO) and total deaths in the ESVEM trial in all 486 pa-
tients randomized. Deaths were OH-AD if arrhythmic death occurred OH or
if out of hospital arrhythmias preceded admission and directly caused death.
OH AD accounted for 41 % of all deaths. Baseline characteristics were CDm-
parable for OH-AD and IH-AD groups (e.g., ejection fraction, disease etiology.
sex, age, beta blocker use, prior antiarrhythmic drug failure). Eighty-six per-
cent of OH deaths were AD while 22% of IH deaths were AD (P < 0.001).
Twenty of 87 arrhythmic deaths occurred in the hospital.
